Ligand Pharmaceuticals Incorporated (LGND) Stock Analysis

Free AI-powered analysis and research for Ligand Pharmaceuticals Incorporated stock

Sector: Healthcare

Analyze Ligand Pharmaceuticals Incorporated (LGND) Stock

Ligand Pharmaceuticals Incorporated (LGND) is a leading company in the Healthcare sector. Use StockIQ's free analysis tool to get comprehensive insights into LGND stock performance, technical indicators, and AI-powered trading recommendations.

Get instant AI-powered analysis including technical indicators, fundamental analysis, risk assessment, and trading insights for Ligand Pharmaceuticals Incorporated stock.

Analyze LGND Now →

📰 Latest Update

Ligand Pharmaceuticals to Buy XOMA Royalty for $39/Share, Lifts 2026 Guidance and EPS Outlook

Mon, April 27, 2026 at 11:13 PM UTC 3 min read

Ligand Pharmaceuticals has announced its acquisition of XOMA's royalty rights for $39 per share, a move that is expected to enhance its revenue stream. The company also raised its guidance for 2026 and improved its earnings per share outlook, signaling confidence in future growth. This acquisition could strengthen Ligand's market position and provide investors with increased potential returns.

Read full article →